Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-985521
BMS-986521 · 2 trials · 1 indication
Based on PET scans
| Arm | Type | Description |
|---|---|---|
| BMS-986521: Cohort 1 | EXPERIMENTAL | - |
| BMS-986521: Cohort 2 | EXPERIMENTAL | - |
| BMS-986521: Cohort 3 | EXPERIMENTAL | - |
| Part A Cohort 1 | EXPERIMENTAL | - |
| Part A Cohort 2 | EXPERIMENTAL | - |
| Part A Cohort 3 | EXPERIMENTAL | - |
| Part A Cohort 4 | EXPERIMENTAL | - |
| Part A Cohort 5 | EXPERIMENTAL | - |
| Part A Cohort 6 | EXPERIMENTAL | - |
| Part B Cohort 7 | EXPERIMENTAL | - |
| Part B Cohort 8 | EXPERIMENTAL | - |
| Part B Cohort 9 | EXPERIMENTAL | - |
| Part B Cohort 10 | EXPERIMENTAL | - |
| Part B Cohort 11 | EXPERIMENTAL | - |
| Part C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986521 | DRUG | Specified dose on specified days |
| BMS-985521 | DRUG | Specified dose on specified days. |
| Placebo | OTHER | Specified dose on specified days |
Inclusion Criteria: * Participants must be healthy male and female (as assigned at birth) who are individuals not of childbearing potential (INOCBP) without clinically significant deviation from normal in medical history, PE, 12-lead ECG, and clinical laboratory assessments. * Participants must hav...
BMS-986521 is an investigational small molecule being developed by Bristol-Myers Squibb Company. It is in Phase 1 clinical development, with two active trials currently recruiting healthy adult participants. No patient indication has been disclosed for the program.
BMS-986521 targets the M4 muscarinic acetylcholine receptor. One Phase 1 positron emission tomography study is designed to assess occupancy of M4 muscarinic acetylcholine receptors by BMS-986521 in healthy adult participants, which indicates the receptor is the intended molecular target of the compound.
Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY, is developing BMS-986521. The company is the sponsor of both Phase 1 trials of the small molecule that are currently listed as recruiting.
BMS-986521 is in Phase 1 clinical development. It is an investigational small molecule and is not approved for any use. Two Phase 1 trials are active and recruiting, and no trials for the program have been completed.
BMS-986521 is being studied in two recruiting Phase 1 trials. NCT07655518 is a positron emission tomography study assessing M4 muscarinic acetylcholine receptor occupancy in healthy adults in Belgium. NCT07283263 evaluates safety, tolerability, and drug levels in healthy participants in the United States.
Yes, BMS-985521 is an alternative name for BMS-986521. Both names refer to the same investigational small molecule from Bristol-Myers Squibb Company, so searches using either designation point to the same Phase 1 development program.